SLU-PP-332 (Pan-ERR Agonist Exercise Mimetic)
✅ Synthetic small-molecule pan-agonist of ERRα/β/γ nuclear receptors
✅ Direct transcriptional driver of mitochondrial biogenesis + oxidative-fibre induction
✅ Leading exercise-mimetic research compound (Billon et al. 2023, ACS Chem Biol)
✅ EC₅₀ ERRα ~98 nM; ~4-fold ERRα-selective over ERRγ
✅ Some suppliers label as SLU-PP-322; canonical name SLU-PP-332; CAS 303760-60-3, MW 290.32
SLU-PP-332 contains synthetic pan-ERR small-molecule research compound. Not a peptide.
✓ Медицински преглед от Morgan Ellis — Фармацевтичен изследовател · 8 години опит · Последен преглед: май 2026 г.
Quick Answer — What is SLU-PP-332?
SLU-PP-332 (CAS 303760-60-3, MF C18H14N2O2, MW 290.3 g/mol) is a synthetic small-molecule pan-agonist of estrogen-related receptors (ERRα / ERRβ / ERRγ) developed in the Burris laboratory at Saint Louis University. ERRs are orphan nuclear-receptor transcription factors that drive mitochondrial biogenesis, fatty-acid oxidation, oxidative-fibre development, and the muscle-adaptation programme normally engaged by exercise — making SLU-PP-332 a leading “exercise mimetic” research tool. Published in Billon et al. (2023, ACS Chemical Biology) — acute single-dose drives an aerobic-exercise-response gene signature in skeletal muscle; chronic dosing increases Type IIa oxidative-fibre proportion and improves endurance capacity in mice. Small molecule — not a peptide. Note: some supplier batches are labelled SLU-PP-322 / SLU-PP-332 interchangeably — both refer to the same Burris-lab ERR pan-agonist; consult COA for batch-specific identification. For laboratory research use only.
📦 Всяка поръчка е покрита от нашата Политика за повторна изпратка — ако вашата пратка не пристигне в рамките на 20 работни дни, ние я изпращаме отново.
| Спецификация | Детайл |
|---|---|
| Compound Class | Synthetic small-molecule pan-agonist of estrogen-related receptors (ERRα / ERRβ / ERRγ); orphan nuclear-receptor agonist; exercise-mimetic research tool; not a peptide |
| Chemical Name | SLU-PP-332 (synonyms: SLU-PP-322 in some supplier batches; pan-ERR agonist; Burris-lab Compound 332) |
| CAS номер | 303760-60-3 (canonical, per MedKoo / MedChemExpress / scientific literature) |
| Молекулна формула | C18H14N2O2 |
| Молекулно тегло | 290.32 g/mol |
| Mechanism | Pan-agonist of ERRα, ERRβ, ERRγ nuclear receptors with ~4-fold ERRα selectivity over ERRγ. EC50 ERRα ~98 nM (Billon et al. 2023). ERR receptor activation drives transcription of PGC-1α target genes — mitochondrial biogenesis (TFAM, NRF1, NRF2), fatty-acid β-oxidation (CPT1B, MCAD, LCAD), oxidative-phosphorylation complex subunits, and oxidative-fibre-type myosin heavy chains. Net effect mimics the transcriptional programme of exercise adaptation. |
| Последователност | n/a (small-molecule synthetic compound — not a peptide) |
| Форма | Lyophilized white-to-off-white powder; single-use research vials |
| Чистота | ≥99% (HPLC проверено, сертификат за анализ по заявка) |
| Разтворимост | DMSO ≥50 mg/mL; aqueous solubility moderate (sub-mg/mL). For in-vitro work, prepare DMSO stocks and dilute into culture medium just before use. For in-vivo work, formulations typically use DMSO/PEG/saline or similar co-solvent systems. |
| Съхранение | Lyophilized: 2–8 °C short-term, −20 °C long-term (≥36 months). Reconstituted DMSO: −20 °C, single-thaw use. Protect from light. Avoid repeated freeze-thaw. |
| За изследователска употреба | For laboratory research use only. Not for human or veterinary diagnostic or therapeutic use. Not currently on the WADA Prohibited List under its specific name, but researchers should be aware that the broader S4 (Hormone and Metabolic Modulators) class includes exercise-mimetic compounds and SLU-PP-332’s regulatory status may evolve. |
Mechanism of Action — Pan-ERR Agonism Drives Exercise-Adaptation Transcription
SLU-PP-332 is the most-cited synthetic small-molecule ERR pan-agonist in the published literature. ERRs (estrogen-related receptors α, β, γ) are orphan nuclear receptors that share the DNA-binding domain of estrogen receptors but do not bind estrogen — they are constitutively active in the absence of any natural endogenous ligand and instead are regulated by coactivator-binding (most importantly PGC-1α). ERRs are the principal transcriptional drivers of:
- Mitochondrial biogenesis — direct transcriptional control of TFAM, NRF1, NRF2, and dozens of mitochondrial-protein-import genes
- Fatty-acid β-oxidation — induction of CPT1B (carnitine palmitoyltransferase 1B), MCAD, LCAD, and other β-oxidation enzymes
- Oxidative phosphorylation — transcription of nuclear-encoded ETC complex subunits
- Oxidative-fibre development — Type IIa (oxidative fast-twitch) myosin heavy chain induction; conversion from glycolytic Type IIb fibres to oxidative Type IIa fibres
- Glucose-handling adaptation — improved skeletal-muscle insulin sensitivity in DIO mouse models
This is the same transcriptional programme that is engaged by PGC-1α-driven exercise adaptation — making pan-ERR agonism a direct pharmacological route to the exercise-adaptation phenotype. The Billon et al. (2023) ACS Chemical Biology paper demonstrated that acute single-dose SLU-PP-332 produces a gene-expression signature in mouse skeletal muscle that overlaps substantially with the signature produced by a bout of voluntary wheel-running — and chronic dosing (50 mg/kg/d IP for 4 weeks) increases Type IIa fibre proportion and treadmill endurance in mice. Follow-up work (Billon et al. 2024, alleviation of metabolic syndrome) has demonstrated metabolic-improvement effects in DIO mice including glucose-tolerance improvement and reduced hepatic steatosis.
Published Research Applications
- Pan-ERR receptor pharmacology — canonical reference small-molecule ERR pan-agonist
- Exercise-mimetic transcriptional research — published as the leading “exercise in a pill” compound alongside AICAR; mechanistically distinct (ERR-direct vs AMPK-AMP-mimetic)
- Mitochondrial biogenesis research — direct transcriptional driver of TFAM / NRF1 / NRF2 axis
- Skeletal-muscle adaptation research — Type IIa oxidative-fibre induction, endurance-performance phenotype
- Metabolic-syndrome research — DIO mouse models, hepatic steatosis, insulin sensitivity
- PGC-1α pathway pharmacology — engages PGC-1α-driven transcriptional cascade from downstream
For broader context see AICAR (canonical AMPK-mediated exercise mimetic — different mechanism), AOD-9604 (lipolytic-only fat-loss research peptide), MOTS-c (mitochondrial-derived peptide), 5-Амино-1MQ (NAD-axis NNMT inhibitor), NAD⁺ (electron-transport coenzyme).
Available Strengths
| Сила на флакона | Размери на опаковките |
|---|---|
| 5 mg — research standard; supports DIO mouse cohorts at 50 mg/kg/d ×4–8 wk and in-vitro pharmacology at nM-µM concentrations | 10 или 20 флакона |
How It Compares — SLU-PP-332 vs AICAR
SLU-PP-332 and AICAR are the two most-cited “exercise mimetic” research compounds in this catalogue, but they engage the exercise-adaptation programme through mechanistically distinct upstream routes. SLU-PP-332 directly activates the ERR family (the downstream transcription factor for the mitochondrial-biogenesis programme). AICAR activates AMPK (the upstream energy-sensor kinase that, among many other effects, drives PGC-1α expression and PGC-1α-ERR co-activation). The two compounds therefore converge on the same downstream gene-expression signature but engage it from different points of the regulatory cascade.
| Критерий | SLU-PP-332 | AICAR |
|---|---|---|
| MW | 290.32 g/mol | 258.23 g/mol |
| Mechanism | Direct ERRα/β/γ nuclear-receptor agonist | AMPK activator (via intracellular ZMP) |
| Point of intervention | Downstream transcription factor | Upstream energy-sensor kinase |
| Best-studied focus | Type IIa oxidative-fibre induction, endurance phenotype | Insulin sensitivity, hepatic gluconeogenesis, broader AMPK pharmacology |
| Typical dose | 50 mg/kg/d IP (mouse, Billon protocol) | 250–500 mg/kg/d IP (mouse) |
| WADA status | Not currently named | Prohibited at all times (S4.5) |
Съхранение и реконституиране
Lyophilized vials: store at 2–8 °C short-term, −20 °C long-term. Reconstitute in DMSO at ≥10 mg/mL working stock (aqueous solubility is limited; DMSO is the preferred solvent). For in-vivo work, formulate with co-solvents (DMSO/PEG-400/saline or similar) just before administration. Store DMSO stocks at −20 °C, single-thaw use. Protect from light. Avoid repeated freeze-thaw.
FAQ
Is “SLU-PP-322” the same as SLU-PP-332?
Some supplier batches use “SLU-PP-322” and “SLU-PP-332” interchangeably for the same Burris-lab ERR pan-agonist. The canonical scientific designation is SLU-PP-332 (Billon et al. 2023, ACS Chemical Biology), with CAS 303760-60-3. Consult batch COA for definitive identification.
What published dose ranges have been used?
Mouse in-vivo protocols use 50 mg/kg/d IP for 4–8 weeks (Billon et al. canonical protocol). In-vitro myotube and primary muscle-cell pharmacology uses 100 nM to 10 µM in growth medium. EC50 on ERRα is ~98 nM.
How is SLU-PP-332 different from other exercise mimetics?
SLU-PP-332 directly activates ERRs — the downstream transcription factors. AICAR activates AMPK (upstream kinase). The 2010s-vintage PPARδ agonists (GW501516) activate a different but partially-overlapping transcriptional programme. Different mechanism, partially-overlapping output.
Is SLU-PP-332 on the WADA Prohibited List?
Not currently under its specific name, but the broader S4 class (Hormone and Metabolic Modulators) includes exercise-mimetic compounds. The compound’s regulatory status may evolve as more research data accumulates. Researchers in human-subject contexts should consult the current WADA list.
Other Exercise-Mimetic / Metabolic Research Compounds
- AICAR — Canonical AMPK-mediated exercise mimetic — complementary mechanism
- AOD-9604 — Lipolytic-only hGH C-terminal fragment
- MOTS-c — Mitochondrial-derived metabolic peptide AMPK activator
- 5-Амино-1MQ — NNMT inhibitor — NAD-axis precursor sparing
- NAD⁺ — Direct dinucleotide pool supplementation
- BAC вода (Бактериостатична вода) — Required for reconstituting any lyophilized vial — sterile, 0.9% benzyl-alcohol-preserved diluent
Още опции в Пептиди
Класирани според скорошния обем на поръчки в MedsBase — какво избират други клиенти в тази категория.
| Сила | 5 mg |
|---|---|
| Количество | 10 флакона, 20 флакона, 30 флакона |
SLU-PP-332 (Pan-ERR Agonist Exercise Mimetic)
Въпроси и отговори
SLU-PP-332 (Pan-ERR Agonist Exercise Mimetic)
Свързани продукти
Отзиви
Все още няма отзиви